RUBINSTEIN: "THE CHALLENGE IS THAT INNOVATION IN HEALTH REACHES ALL ALIKE"
Government Secretary of Health participated in a panel discussion on the
impact of the results of research and development in life expectancy and
collaborative work to be accessible to society.
Tuesday May 28, 2019
"We are experiencing challenging and wonderful as to the implications and
consequences of technological innovation in improving the quality and life
expectancy times," said today the Government Secretary of Health, Adolfo
Rubinstein, in the third edition of Janssen medical Innovation Day which
brought together national authorities, doctors, pharmaceutical industry
professionals and related health system.
Rubinstein listed various advances as new diagnostic devices, artificial
intelligence, Big Data, gene therapy and cell therapy affecting the quality
of life and said that "as a health authority we have to think how these
benefits reach alike. The challenge is that innovation in health reaches
all alike ".
In the panel discussion on innovation in health, government secretary of
Health said the question is "how to work together in a way that on the one
hand, encouragement and incentive for technological innovation persist yet
once note that we can not continue widening inequality gaps that exist in
our country and the world ".
Rubinstein was accompanied by Secretary of Government for Science,
Technology and Productive Innovation, Lino Barañao; Secretary of Planning
and Policies in Science, Technology and Innovation, Jorge Aguado; Vice
President of the Executive Committee of Johnson & Johnson, Paul Stoffels
and director of Janssen (pharmaceutical company Johnson & Johnson) The
South. The panel was moderated by Vice President of External Affairs of
Science and Medicine Johnson & Johnson, Carlos Castillejos.
On the other hand, Rubinstein emphasized the importance of the bill for the
creation of the National Agency for the Evaluation of Health Technologies
(AGNET), which is now in the Senate of the Nation, "to be able to clearly
define what are the criteria by which they will prioritize the coverage of
new technologies ". He further stated that "the creation of the agency
allows you to define policies explicit, objective, transparent and clear
criteria cover".
In turn Barañao spoke about the importance of partnership between basic
science that may arise in Argentine laboratories and major companies that
can turn this knowledge into effective treatment, and on mechanisms that
allow this cooperation. He stressed "the possibility of regional
complementarity in Latin America, especially in diseases that affect our
populations."
Meanwhile, Stoffels developed different lines of research carried out by
the pharmaceutical company Janssen and Roy Benchimol said that "clinical
research is the engine that allows us to advance science making possible
new and better treatment options," so that " from the collaboration between
all sectors and fruitful dialogue based on science can build together the
proposals so that people can have a better and longer life. "
impact of the results of research and development in life expectancy and
collaborative work to be accessible to society.
Tuesday May 28, 2019
"We are experiencing challenging and wonderful as to the implications and
consequences of technological innovation in improving the quality and life
expectancy times," said today the Government Secretary of Health, Adolfo
Rubinstein, in the third edition of Janssen medical Innovation Day which
brought together national authorities, doctors, pharmaceutical industry
professionals and related health system.
Rubinstein listed various advances as new diagnostic devices, artificial
intelligence, Big Data, gene therapy and cell therapy affecting the quality
of life and said that "as a health authority we have to think how these
benefits reach alike. The challenge is that innovation in health reaches
all alike ".
In the panel discussion on innovation in health, government secretary of
Health said the question is "how to work together in a way that on the one
hand, encouragement and incentive for technological innovation persist yet
once note that we can not continue widening inequality gaps that exist in
our country and the world ".
Rubinstein was accompanied by Secretary of Government for Science,
Technology and Productive Innovation, Lino Barañao; Secretary of Planning
and Policies in Science, Technology and Innovation, Jorge Aguado; Vice
President of the Executive Committee of Johnson & Johnson, Paul Stoffels
and director of Janssen (pharmaceutical company Johnson & Johnson) The
South. The panel was moderated by Vice President of External Affairs of
Science and Medicine Johnson & Johnson, Carlos Castillejos.
On the other hand, Rubinstein emphasized the importance of the bill for the
creation of the National Agency for the Evaluation of Health Technologies
(AGNET), which is now in the Senate of the Nation, "to be able to clearly
define what are the criteria by which they will prioritize the coverage of
new technologies ". He further stated that "the creation of the agency
allows you to define policies explicit, objective, transparent and clear
criteria cover".
In turn Barañao spoke about the importance of partnership between basic
science that may arise in Argentine laboratories and major companies that
can turn this knowledge into effective treatment, and on mechanisms that
allow this cooperation. He stressed "the possibility of regional
complementarity in Latin America, especially in diseases that affect our
populations."
Meanwhile, Stoffels developed different lines of research carried out by
the pharmaceutical company Janssen and Roy Benchimol said that "clinical
research is the engine that allows us to advance science making possible
new and better treatment options," so that " from the collaboration between
all sectors and fruitful dialogue based on science can build together the
proposals so that people can have a better and longer life. "